Total Funding
76
64
Total FundingPrivate Equity raised
Growth Score 76 in past quarter
-13 pts
Heat Score 64 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
6217
Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.
Acquired by 
Gilead Sciences
- Bruce Booth: Co-FounderPast Role: Caxton Associates, Principal
Ramy Farid: Co-Founder and DirectorPast Role: Rutgers University, Assistant Professor of Chemistry
Gilead Sciences
About the Company
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical-stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical
development. Nimbus Therapeutics designs highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer, and immune-inflammatory disorders.
